Boehringer Ingelheim (United States)

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. Boehringer Ingelheim (Germany)德国6
2. Brigham and Women's Hospital美国2
3. Harvard University美国2
4. Universidad Complutense de Madrid西班牙1
5. Boston University美国1
6. Centro Español de Investigación Farmacoepidemiológica西班牙1
7. Stony Brook University Hospital美国1
8. KU Leuven比利时1

按月发文

逐年被引

最新文献

1. 1
   Association between access to care and direct healthcare costs in people with and at high-risk of chronic kidney disease in the United States: a pooled cross-sectional study using the Medical Expenditure Panel SurveyBMC Public Health20260
2. 2
   Using Quantitative Bias Analysis to Adjust for Misclassification of COVID ‐19 Outcomes: An Applied Example of Inhaled Corticosteroids and COVID ‐19 OutcomesPharmacoepidemiology and Drug Safety20256
3. 3
   Risk of acute pancreatitis among new users of empagliflozin compared to sulfonylureas in patients with type 2 diabetes: A post‐authorization safety studyPharmacoepidemiology and Drug Safety20243
4. 4
   Confirming diagnoses of acute pancreatitis with commonly available electronic dataPharmacoepidemiology and Drug Safety20202
5. 5
   Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trialsExpert Opinion on Drug Safety202013
6. 6
   A concept‐wide association study to identify potential risk factors for nonadherence among prevalent users of antihypertensivesPharmacoepidemiology and Drug Safety20197
7. 7
   Development and validation of algorithms to identify newly diagnosed type 1 and type 2 diabetes in pediatric population using electronic medical records and claims dataPharmacoepidemiology and Drug Safety201920
8. 8
   Real world management of pregestational diabetes not achieving glycemic control for many patients in the UKPharmacoepidemiology and Drug Safety20185
9. 9
   Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter ReviewAnnals of Emergency Medicine20178
10. 10
    Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjectsAmerican Journal of Emergency Medicine201628

高被引文献

1. 1
   Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjectsAmerican Journal of Emergency Medicine201628
2. 2
   Development and validation of algorithms to identify newly diagnosed type 1 and type 2 diabetes in pediatric population using electronic medical records and claims dataPharmacoepidemiology and Drug Safety201920
3. 3
   Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trialsExpert Opinion on Drug Safety202013
4. 4
   INITIAL RESULTS OF THE RE-VERSE AD TRIAL: IDARUCIZUMAB REVERSES THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY OR INTERVENTIONSEmergency Medicine Journal20158
5. 5
   Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter ReviewAnnals of Emergency Medicine20178
6. 6
   A concept‐wide association study to identify potential risk factors for nonadherence among prevalent users of antihypertensivesPharmacoepidemiology and Drug Safety20197
7. 7
   Using Quantitative Bias Analysis to Adjust for Misclassification of COVID ‐19 Outcomes: An Applied Example of Inhaled Corticosteroids and COVID ‐19 OutcomesPharmacoepidemiology and Drug Safety20256
8. 8
   Real world management of pregestational diabetes not achieving glycemic control for many patients in the UKPharmacoepidemiology and Drug Safety20185
9. 9
   Risk of acute pancreatitis among new users of empagliflozin compared to sulfonylureas in patients with type 2 diabetes: A post‐authorization safety studyPharmacoepidemiology and Drug Safety20243
10. 10
    Confirming diagnoses of acute pancreatitis with commonly available electronic dataPharmacoepidemiology and Drug Safety20202

主要发表期刊